NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Nuevocor

Nuevocor

Private
SingaporeHealthcare & Life Scienceshttps://www.nuevocor.com/

Last Round

Series B

May 6, 2025

Total Funding Raised

$69M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

Nuevocor is a biotechnology company that develops gene therapies for cardiomyopathies driven by aberrant mechanobiology.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

gene therapygenetic cardiomyopathyLMNA-associated cardiomyopathybiotechprecision medicineclinical trialsdrug discoverygenetic medicinerare disease therapyheart disease researchbiopharmatherapeutic development

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Nuevocor Comparables

Compare Nuevocor with similar companies based on industry and business-model similarity.

Nuevocor comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Affinia Therapeutics
79%
DiNAQOR AG
76%
Bayer AG
74%

Nuevocor Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BMay 6, 2025
Series AJun 18, 2021

Key People

Founding team and executive leadership

Yann Chong Tan

Co-founder And Chief Executive Officer

Founding Team

Nuevocor Investors

Notable investors and investment history

Nuevocor investors
InvestorRounds
Xora InnovationSeries B, Series A
SEEDS CapitalSeries B, Series A
Highlight CapitalSeries B
ClavystBioSeries B
EDBISeries B, Series A
Angelini VenturesSeries B
EVX VenturesSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 28, 2026

    First-in-human study of NVC-001 for LMNA-associated DCM to begin.

  • Apr 28, 2026

    Dr. Shah appointed to lead global clinical development and medical affairs.

Nuevocor Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Nuevocor Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Nuevocor's valuation, stock price, and market status.

Firmographic Details

HeadquartersSingapore
Employee Range29
Year Founded2021
Last FundingMay 6, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.